Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
VanEck Pharmaceutical Fund Bets Big on Weight-Loss Drug Market Approaching $150 Billion
10:36am, Friday, 23'rd Jan 2026
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund's concentrated bet on GLP-1 manufacturers makes this
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?
10:00am, Friday, 23'rd Jan 2026
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record
09:12am, Friday, 23'rd Jan 2026
Novo Nordisk A/S' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one
Novo's Wegovy pill tracks 18,410 prescriptions for first full week since launch
07:32am, Friday, 23'rd Jan 2026
Novo Nordisk's Wegovy pill tracked 18,410 U.S. prescriptions in the first full week after its launch, IQVIA data shared by an analyst on Friday showed.
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
07:00am, Friday, 23'rd Jan 2026
Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment options and improved access for patients. CNBC spo
Final Trade: SII, C, SMH, NVO
06:18pm, Thursday, 22'nd Jan 2026
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
Sesame Launches Wegovy® Pill Through Collaboration With Novo Nordisk
09:00am, Thursday, 22'nd Jan 2026
NEW YORK--(BUSINESS WIRE)--SESAME LAUNCHES WEGOVY® PILL THROUGH COLLABORATION WITH NOVO NORDISK.
Novo Nordisk (NVO) Stock Slides as Market Rises: Facts to Know Before You Trade
06:45pm, Wednesday, 21'st Jan 2026
Novo Nordisk (NVO) closed the most recent trading day at $59.32, moving 2.24% from the previous trading session.
Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026
11:20am, Wednesday, 21'st Jan 2026
Novo Nordisk A/S is poised for a turnaround in 2026, driven by renewed strategic focus under new CEO Maziar Doustdar. NVO's core strengths in diabetes and obesity, particularly with semaglutide, under
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies
11:16am, Wednesday, 21'st Jan 2026
Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.
Novo: Back From The Dead
09:15am, Wednesday, 21'st Jan 2026
Novo Nordisk has rebounded over 40% after a sharp 2025 sell-off, driven by renewed optimism for its oral Wegovy launch. Valuation reset, strong technicals, and an underappreciated pipeline make NVO at
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Jan 2026)
08:20am, Wednesday, 21'st Jan 2026
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and up to $25 billion projected for 2025, it shows no signs of slowing down, much to the
Is Oral Wegovy a Game Changer for Novo Nordisk?
02:45pm, Tuesday, 20'th Jan 2026
Novo Nordisk just launched an oral version of its popular weight-loss therapy, Wegovy. This move might help it make some headway in an increasingly competitive market.
Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
12:18pm, Tuesday, 20'th Jan 2026
Drug pricing, looming patent cliffs, dealmaking, and the first year of the second Trump administration dominated conversations at the annual JPMorgan Healthcare Conference in San Francisco. Top exe
Novo Nordisk expands diabetes cell therapy partnership with Aspect Biosystems
09:28am, Tuesday, 20'th Jan 2026
Danish drugmaker Novo Nordisk and Canada-based privately held Aspect Biosystems said on Tuesday they have struck a partnership to develop cell-based treatments for diabetes.
